Ivan Kairatov is a Biopharma expert with extensive knowledge in technology and innovation within the industry and considerable experience in research and development. Today, we discuss the newly introduced Genomic Data Protection Act (GDPA) and its implications. Can you explain the main purpose of
Clinical trials have long been criticized for their lack of diversity, particularly in the participation of women. Historically, such exclusions have led to significant gaps in medical knowledge and treatment efficacy across genders, resulting in potentially biased outcomes for a substantial
In a surprising move, Sutro Biopharma has decided to undertake a sweeping restructuring plan with the primary goal of conserving capital, leading to a nearly 50% reduction in its workforce, the ousting of CEO Bill Newell, the discontinuation of its lead drug candidate luveltamab tazevibulin
As the Biden administration prepared to leave office, it enacted a significant order titled "HIPAA Security Rule to Strengthen the Cybersecurity of Electronic Protected Health Information." This order could potentially destabilize the healthcare sector's financial and operational
In 2025, Federally Qualified Health Centers (FQHCs) and Community Health Centers (CHCs) across the United States will undergo transformative regulatory changes. These changes will impact data reporting, preventive services billing, and care management billing, necessitating comprehensive
In today's interconnected world, the healthcare industry faces increasingly sophisticated cyber threats that could jeopardize patient data and safety. Cyber-attacks on medical practices and facilities are becoming more frequent, highlighting vulnerabilities that need immediate addressing.
